Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults

Part of paid clinical trials in Beverly Hills, California.

Sponsor
Scott Silveira
Study ID
NCT07144527
Status
Recruiting
Apply to this trial

Conditions

  • Aging
  • Exercise Tolerance
  • Frailty
  • Healthy Male and Female Subjects

Eligibility Criteria

Sex
ALL
Age
60 Years - 80 Years
Healthy Volunteers
Accepted

Interventions

  • NMN, betaine, low-dose hydrogen peroxide (EGA) — DIETARY_SUPPLEMENT
    Proprietary formulation containing NMN, betaine, and low-dose hydrogen peroxide.
  • Nicotinamide Mononucleotide (NMN) — DIETARY_SUPPLEMENT
    Conventional NMN supplement.
  • Placebo — DIETARY_SUPPLEMENT
    Organoleptically matched inert control.

Study Details

This is a randomized, double-blind, placebo-controlled, two-arm crossover clinical trial evaluating the effects of a patented age-reversal therapy, EGA®, compared to conventional nicotinamide mononucleotide (NMN) supplementation. The study will assess safety and efficacy in improving exercise tolerance and modulating biomarkers of aging in healthy older adults. The primary outcome is cycle ergometry constant work rate (CWR) exercise tolerance, measured as time to fatigue. Secondary outcomes include changes in peak oxygen consumption (VO₂peak), critical power, anaerobic work capacity, lactate threshold, and NAD⁺ metabolite levels. EGA® is composed of three metabolomic compounds that are endogenous to humans. The formulation has been used in prior exploratory studies and real-world applications, which have helped inform the design of this current trial.

Key Dates

Start date
Feb 21, 2026
Status verified
Feb 2026
Primary completion
Dec 30, 2026
Completion
Jan 1, 2027

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Arm 1 - EGA -> Placebo
    Participants receive EGA during Period 1, followed by Placebo during Period 2 after a washout. Assigned Interventions: EGA; Placebo.
  • Experimental: Arm 2 - Placebo -> EGA
    Participants receive Placebo during Period 1, followed by EGA during Period 2 after a washout. Assigned Interventions: Placebo; EGA.
  • Experimental: Arm 3 - NMN -> Placebo
    Participants receive Nicotinamide Mononucleotide (NMN) during Period 1, followed by Placebo during Period 2 after a washout. Assigned Interventions: NMN; Placebo.
  • Experimental: Arm 4 - Placebo -> NMN
    Participants receive Placebo during Period 1, followed by NMN during Period 2 after a washout. Assigned Interventions: Placebo; NMN.

Primary Outcome Measure

Time to Fatigue During Constant Work Rate Cycle Ergometry (tLIM). [ Time Frame: Measured at the beginning and end of each 4-week intervention period. ]

Locations (1)

FacilityCityStateZIPSite coordinators
Medical Office of Dr. Robert Huizenga MDBeverly HillsCalifornia90210
Nancy Castellanos, BA
[email protected]
310-666-6585
Ashley Erazo, Medical Assistant
[email protected]
310-657-9191
Scott R Silveira, Ph.D. (c) (PRINCIPAL_INVESTIGATOR)

Find similar trials in Beverly Hills, CA

By research site
Medical Office of Dr. Robert Huizenga MD· Beverly Hills, CA

Related Studies